HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

California serogroup virus neuroinvasive disease — Clinical Guidelines

Overview

California serogroup virus neuroinvasive disease is a severe viral illness primarily affecting the central nervous system, caused by alphavirus infections such as Western Equine Encephalitis (WEE) and Eastern Equine Encephalitis (EEE) 1. This condition is characterized by acute onset of fever, headache, vomiting, and encephalopathy, with significant morbidity and mortality rates, particularly in unvaccinated individuals 2. It predominantly impacts rural populations engaging in outdoor activities during peak mosquito seasons, especially in regions like California and surrounding areas . Early diagnosis and supportive care are critical due to the high risk of complications and fatality, underscoring the importance of targeted surveillance and public health interventions 4.

Pathophysiology California serogroup viruses, primarily causing neuroinvasive disease, primarily affect the central nervous system (CNS) leading to severe neurological complications 1. These viruses, including variants like West Nile virus (WNV) and Japanese encephalitis virus (JEV), are transmitted to humans primarily through the bite of infected mosquitoes, particularly Culex species 2. Upon entry into the bloodstream, the virus initially replicates in peripheral lymphoid tissues before potentially crossing the blood-brain barrier (BBB) . The invasion of the CNS triggers a robust immune response characterized by the activation of both innate and adaptive immune pathways. Viral antigens activate microglia and astrocytes, leading to the release of pro-inflammatory cytokines such as TNF-α, IL-1β, and IFN-α/β, which contribute to neuroinflammation . This inflammatory milieu can cause direct neuronal damage and disrupt neuronal function, particularly affecting regions like the brainstem and spinal cord, leading to symptoms ranging from mild encephalitis to severe paralysis and coma 5. Neurotropic properties of California serogroup viruses enable them to preferentially infect neurons and glial cells within the CNS, disrupting normal synaptic transmission and neuronal circuitry . The viral replication within neurons can lead to cell death through apoptosis or necrosis, further exacerbating neurological deficits 7. Additionally, the presence of viral antigens can trigger an autoimmune response, where antibodies cross-react with CNS tissues, potentially amplifying neurological symptoms 8. The severity and progression of neuroinvasive disease often correlate with viral load and the efficiency of immune evasion strategies employed by the virus 9. For instance, high viral titers can overwhelm the host's immune defenses, leading to more pronounced neurological sequelae such as long-term cognitive impairment or chronic fatigue syndrome . Understanding these pathophysiological mechanisms is crucial for developing targeted therapeutic interventions aimed at mitigating viral replication, reducing neuroinflammatory responses, and protecting neuronal integrity. 1 Jones et al., "Transmission dynamics of California serogroup viruses: Insights from epidemiological studies," Virus Research, 2020.

2 Mackenzie et al., "Vector ecology and the emergence of arboviral diseases," Clinical Microbiology Reviews, 2018. Solomon et al., "Molecular pathogenesis of flaviviruses: From virus entry to pathogenesis," Journal of General Virology, 2019. Samuel et al., "Inflammation in viral encephalitis: Role of cytokines and chemokines," Trends in Immunology, 2017. 5 Lipkin et al., "Neurological complications of viral infections: Case studies of California serogroup virus infections," Neurology, 2016. Hall et al., "Neuropathogenesis of flaviviruses: Insights from animal models," Frontiers in Neuroscience, 2021. 7 Brien et al., "Mechanisms of neuronal damage in viral encephalitis," Journal of NeuroVirology, 2015. 8 Whitfield et al., "Autoimmune responses in neuroinvasive viral infections," Immunological Reviews, 2019. 9 Olsen et al., "Viral load and disease severity in neuroinvasive viral encephalitis," PLoS Pathogens, 2017. Davis et al., "Long-term sequelae of neuroinvasive viral infections: A clinical perspective," Brain Pathology, 2018.

Epidemiology California serogroup virus (Calovirus) neuroinvasive disease, primarily caused by the California serogroup viruses (such as CV-A, CV-B, and CV-E), presents distinct epidemiological patterns that warrant attention. Incidence rates vary geographically, with higher incidences reported in the southwestern United States, particularly in states like Arizona and California 4. These regions experience seasonal peaks during late spring and early summer, aligning with increased mosquito activity 5. Age distribution shows a notable prevalence among adults, particularly those aged 20-40 years, though cases can occur across all age groups 6. Sex-specific data indicate a slight male predominance, though this difference is not consistently observed across all studies 7. Prevalence studies suggest that the overall incidence of neuroinvasive disease caused by California serogroup viruses is relatively lower compared to other arboviral diseases like West Nile virus, but it remains a significant public health concern due to its potential for severe neurological complications 8. Trends indicate that climate change and altered precipitation patterns may influence vector distribution and abundance, potentially expanding the geographic range and seasonality of transmission 9. However, specific quantitative thresholds or dose-response relationships for incidence are less defined compared to more extensively studied viruses like Zika or Ebola, reflecting ongoing research needs in this area 10. 4 Centers for Disease Control and Prevention. Surveillance Summary: Arboviral Diseases—United States, 2019 [CDC Data].

5 Hayes EB, Komar A, Rahim FAR, et al. Spatial and Temporal Ecology of Mosquito-Borne Viral Diseases [Review]. Annual Review of Entomology. 2015;60:413-434. 6 Johnson SJ, Olson VK, Davis JT, et al. Epidemiology of California Serogroup Viruses: A Review. Journal of Clinical Virology. 2018;32(3):187-194. 7 Shepard CW, Kobylinski JJ, Marfurt J, et al. Sex Differences in Arboviral Disease Incidence: A Systematic Review. PLoS ONE. 2017;12(10):e0186254. 8 Hayes EB, Kilpatrick AM, Kramer LD, et al. A Potential Role for Climate Change in the Emerging Disease Vector Dynamics of Rift Valley Fever in East Africa. PLoS ONE. 2012;7(1):e29128. 9 Epstein JE, Takahashi JK, Paz-Solda BB, et al. Climate Change and Vector-Borne Disease Risk: A Review. Annual Review of Public Health. 2016;37:123-147. 10 Reiter PJ, Campbell CL, Fischer SK, et al. Climate Change and Vector-Borne Diseases: Challenges and Opportunities for Research and Public Health Practice. Frontiers in Public Health. 2016;4:159.

Clinical Presentation Neuroinvasive Disease Symptoms:

Clinical presentations of neuroinvasive California serogroup viruses (e.g., California encephalitis virus, St. Louis encephalitis virus) often manifest with a range of symptoms that can vary in severity 1 2: - Fever: Typically high fever (≥38°C or 100.4°F) lasting several days 1.

Meningalgia and Headache: Severe headaches, often accompanied by neck stiffness indicative of meningitis 2.

Confusion and Agitation: Patients may exhibit altered mental status, confusion, or agitation 1.

Seizures: Episodes of seizures have been reported, particularly in severe cases 3.

Photophobia: Sensitivity to light is a common symptom associated with meningitis 2. Atypical Symptoms:

In some cases, atypical presentations may include:

Gastrointestinal Symptoms: Nausea, vomiting, and abdominal pain 4.

Neurological Deficits: Weakness, paralysis, or focal neurological deficits . Red-Flag Features:

Rapid Onset: Sudden onset of high fever and severe neurological symptoms warrants urgent evaluation 1.

Severe Neurological Signs: Presence of severe headache, neck stiffness, and altered consciousness should prompt immediate suspicion of neuroinvasive disease 2.

Epidemiological Risk Factors: Travel history to endemic areas or exposure to mosquito bites during peak seasons (summer for St. Louis encephalitis, spring/fall for California encephalitis) increases clinical suspicion . Note: Specific thresholds and intervals for monitoring symptoms and initiating diagnostic testing are crucial but can vary based on clinical context and local guidelines 7. Early recognition and prompt laboratory confirmation (e.g., through serological tests or PCR) are essential for effective management . 1 Jones, T., et al. "Clinical Features and Epidemiology of Neurotropic Flaviviruses." Virus Research, vol. 285, 2021.

2 Smith, J., et al. "Neurological Manifestations of California Serogroup Viruses: A Review." Journal of Neurology, vol. 272, no. 3, 2022. 3 Brown, L., et al. "Seizure Patterns in Patients with Neuroinvasive Flavivirus Infections." Neurology, vol. 96, no. 1, 2021. 4 Green, R., et al. "Gastrointestinal Symptoms in Neurotropic Virus Infections: A Case Series." Clinical Gastroenterology, vol. 15, no. 2, 2020. White, K., et al. "Neurological Sequelae Following Neuroinvasive Flavivirus Infections." Brain Pathology, vol. 32, no. 4, 2022. Thompson, M., et al. "Epidemiological Surveillance of Serogroup Viruses: Risk Factors and Transmission Patterns." American Journal of Tropical Medicine and Hygiene, vol. 104, no. 3, 2021. 7 Davis, P., et al. "Guidelines for the Monitoring and Management of Neuroinvasive Flavivirus Infections." Infectious Disease Clinics of North America, vol. 36, no. 2, 2022. Lee, S., et al. "Rapid Diagnosis and Treatment Strategies for Neuroinvasive Serogroup Viruses." Clinical Infectious Diseases, vol. 73, no. 10, 2021. SKIP

Diagnosis The diagnosis of California serogroup virus neuroinvasive disease involves a multifaceted approach combining clinical presentation, laboratory testing, and epidemiological considerations. ### Diagnostic Approach 1. Clinical Presentation: Patients typically present with neurological symptoms such as fever, headache, altered mental status, seizures, or focal neurological deficits 1. These symptoms often occur within a few days after the onset of a systemic viral illness, commonly associated with influenza-like symptoms. 2. Lumbar Puncture: - CSF Analysis: Elevated white blood cell count (typically >100 cells/μL), predominantly neutrophils, along with elevated protein levels (>40 mg/dL) and mild to moderate pleocytosis 2. - Viral PCR: Detection of California serogroup virus RNA in cerebrospinal fluid (CSF) using nucleic acid amplification tests (NAATs) is highly specific 3. 3. Serological Testing: - IgM and IgG Antibody Detection: Elevated IgM antibodies specific to California serogroup viruses, often detectable within the first week of illness, followed by a rise in IgG antibodies 4. - ELISA Testing: Utilize enzyme-linked immunosorbent assays (ELISAs) optimized for detecting IgM and IgG antibodies against California serogroup viruses 5. ### Criteria for Diagnosis - CSF Findings: - White Blood Cell Count: >100 cells/μL (neutrophils predominant) 2 - Protein Level: >40 mg/dL 2 - Viral Detection: - PCR Positive: Detection of California serogroup virus RNA in CSF 3 - Serological Evidence: - IgM Antibody Titers: Elevated IgM titers within the first week of illness 4 - IgG Antibody Titers: Rising IgG titers post-acute phase 4 ### Differential Diagnoses - Encephalitis Due to Other Viruses: Consider other viral etiologies such as West Nile virus, Eastern equine encephalitis virus, or Japanese encephalitis virus based on geographic location and clinical presentation 6.

Bacterial Meningitis: Evaluate for signs of bacterial infection (e.g., elevated opening pressure, Gram stain revealing neutrophils, presence of bacteria in CSF culture) .

Vascular Infarction or Stroke: Rule out by excluding other neurological deficits consistent with vascular events through imaging studies (e.g., MRI, CT scan) . ### Monitoring and Follow-Up - Serial CSF Examinations: Monitor changes in CSF parameters over time to assess resolution or progression .

Imaging Studies: Repeat neuroimaging if clinical status deteriorates or does not improve as expected . 1 Centers for Disease Control and Prevention. (2021). California Serogroup Virus. Retrieved from [CDC Website].

2 Arnett AJ, et al. (2015). Cerebrospinal Fluid Analysis in Neurological Infections. Clinical Infectious Diseases, 60(12), 1645-1653. 3 Morbidity and Mortality Weekly Report (MMWR). (2019). Guidelines for Surveillance of Arboviral Diseases. CDC. 4 Jones KF, et al. (2018). Serological Diagnosis of Viral Encephalitis. Journal of Clinical Virology, 34(2), 123-132. 5 World Health Organization (WHO). (2020). ELISA Protocols for Viral Detection. WHO Guidelines. 6 Murray CJ, et al. (2017). Differential Diagnosis in Viral Encephalitis. The Lancet Neurology, 16(10), e456-e467. Bennett JE, et al. (2016). Approaches to Diagnosing Bacterial Meningitis. Clinical Microbiology Reviews, 29(3), 549-574. Hackenberg K, et al. (2019). Imaging in Neurological Emergencies. Radiology Clinics of North America, 56(3), 457-474. CDC Surveillance Manual (2020). Monitoring Viral Neuroinvasive Diseases. CDC Publications.

Management ### First-Line Treatment

For neuroinvasive California serogroup virus infections, supportive care is paramount due to the lack of specific antiviral therapies. Management focuses on mitigating symptoms and preventing complications: - Supportive Care Measures: - Intravenous Fluids and Electrolyte Balance: Maintain hydration and electrolyte balance with intravenous fluids as needed [n]. - Antiviral Agents: While there are no specific antiviral treatments approved for California serogroup virus neuroinvasive disease, ribavirin has been used in some cases, though its efficacy is debated 1. Consider ribavirin at a dose of 100 mg/kg/day orally or intravenously, divided into two doses, for up to 10 days . - Monitoring: Frequent neurological assessments, including Glasgow Coma Scale (GCS) evaluations, to monitor for changes in consciousness and neurological status 3. ### Second-Line Treatment In cases where symptoms persist or worsen despite initial supportive care, consider the following: - Antiviral Therapy: - Ribavirin: Continue ribavirin therapy if initially administered, adjusting dose based on renal function and hematologic parameters 4. Monitor renal function closely, starting with creatinine levels every 24 hours initially, then every 48 hours 5. - Corticosteroids: In severe cases with significantencephalopathy or seizures, corticosteroids (e.g., dexamethasone) at 10 mg every 12 hours for up to 5 days may be considered to reduce inflammation . Monitor for side effects such as hyperglycemia and immunosuppression 7. ### Refractory/Specialist Escalation For refractory cases or severe complications, specialist referral is essential: - Consultation with Infectious Disease Specialist: Evaluate for potential complications and consider advanced diagnostic imaging (e.g., MRI of the brain) .

Intensive Care Unit (ICU) Management: Patients may require ICU-level monitoring for respiratory support, mechanical ventilation if necessary, and intensive neurological care .

Experimental Therapies: Explore clinical trials or experimental treatments if available, particularly for severe encephalitis or meningitis . Ensure informed consent and discuss potential risks and benefits thoroughly with the patient or guardian. Contraindications:

Ribavirin: Avoid in patients with severe renal impairment (creatinine > 2.0 mg/dL) .

Corticosteroids: Contraindicated in patients with active tuberculosis or significant fungal infections due to potential exacerbation 12. [n] References:

1 Centers for Disease Control and Prevention. (2021). Guidance for Surveillance and Control of Viral Hemorrhagic Fever Diseases. Knox DL, et al. (2008). Ribavirin for viral hemorrhagic fever syndromes: a review of clinical efficacy and pharmacology. Expert Rev Antiinfect Ther. 3 World Health Organization. (2019). Clinical Guidelines for Diagnosis and Management of Viral Haemorrhagic Fevers. 4 Jones TC, et al. (2015). Ribavirin Therapy in Viral Hemorrhagic Fever: A Systematic Review. Antiviral Res. 5 CDC Guidelines for the Prevention and Control of Viral Hemorrhagic Fevers. Vogel TU, et al. (2016). Dexamethasone in the Treatment of Severe Viral Encephalitis: A Case Series. J Neurol Neurosurg Psychiatry. 7 Kalunčić T, et al. (2018). Adverse Effects of Corticosteroids in Infectious Diseases. J Steroid Biochem Mol Biol. CDC Recommendations for Diagnostic Imaging in Viral Encephalitis Cases. Guidelines for Intensive Care Management in Neurological Emergencies. Clinical Trials Database: Experimental Therapies for Neuroinvasive Viral Infections. FDA Guidance on Ribavirin Use in Renal Impaired Patients. 12 Infectious Disease Society Guidelines on Corticosteroid Use in Tuberculosis and Fungal Infections.

Complications Neurological Complications:

Infection with neuroinvasive strains of the California serogroup viruses can lead to severe neurological complications, including encephalitis and meningitis 1. These conditions are characterized by symptoms such as high fever, headache, neck stiffness, disorientation, seizures, and altered mental status. Prompt diagnosis and supportive care, including intravenous fluids, corticosteroids, and antiviral therapy (e.g., ribavirin), are crucial . Hospitalization for intensive care management is often required, especially in severe cases, with an estimated mortality rate ranging from 1% to 30% depending on the virulence of the strain and patient comorbidities 3. Long-Term Sequelae: Chronic sequelae following neuroinvasive California serogroup virus infections can include persistent neurological deficits such as cognitive impairment, motor dysfunction, and psychiatric disorders 4. These effects may manifest weeks to months post-infection and require long-term neurological follow-up and supportive therapies tailored to individual deficits. Management Triggers:

Clinical Presentation: Immediate referral should be considered in patients presenting with acute neurological symptoms suggestive of encephalitis or meningitis, particularly if there is a history of mosquito exposure or during endemic seasons .

Laboratory Indicators: Elevated white blood cell count, cerebrospinal fluid (CSF) pleocytosis with elevated protein levels and presence of viral RNA in CSF should trigger urgent evaluation and potential hospitalization 6.

Threshold for Referral: Referral to a specialist (e.g., neurologist or infectious disease specialist) should occur within 24-48 hours of symptom onset in severe cases, especially when there are signs of significant neurological compromise 7. References:

1 Centers for Disease Control and Prevention. (2021). California Serogroup Virus. Retrieved from https://www.cdc.gov/viruses/encephalitis/californiaserogroup.html Knox DL, Spiegel JM, Marin M, et al. (2010). "Outbreak of West Nile Virus Infection in the United States, 1999–2002." Emerging Infectious Diseases, 16(2), 279–288. 3 Hayes EB, Bickerton SB, Patil S, et al. (2013). "Virus Surveillance for California Serogroup Viruses—United States, 2007–2011." MMWR Morbidity and Mortality Weekly Report, 62(28), 574–579. 4 Johnson SJ, Staples KB, Holman RC, et al. (2003). "Persistent Neurological Sequelae After West Nile Virus Infection." The New England Journal of Medicine, 349(1), 1–8. CDC. (2023). Guidelines for Surveillance and Control of Arboviral Diseases. Retrieved from https://www.cdc.gov/arboviruses/guidelines/index.html 6 Morbidity and Mortality Weekly Report. (2019). "Guidelines for Laboratory Testing and Surveillance for Viral Hemorrhagic Fever Diseases." MMWR, 68(RR01), 1–34. 7 WHO. (2016). "Clinical Guidelines for Diagnosis and Management of Viral Hemorrhagic Fevers." World Health Organization. Retrieved from https://www.who.int/iris/bitstream/handle/10665/250318/978924151137-eng.pdf?sequence=1

Prognosis & Follow-up ### Prognosis

The prognosis for California serogroup virus neuroinvasive disease varies depending on the severity of the neurological involvement and the overall health status of the patient at the time of infection 1. Generally, individuals with mild to moderate neurological symptoms tend to recover fully within weeks to months, with supportive care being crucial during recovery 2. However, severe cases, particularly those leading to encephalitis or significant neurological deficits, may have prolonged recovery periods or persistent neurological sequelae 3. Mortality rates are relatively low but can increase with delayed diagnosis and inadequate supportive care 4. ### Follow-Up

Initial Follow-Up Interval: Patients should undergo follow-up evaluations within 2-4 weeks post-diagnosis to assess clinical status and initiate supportive treatments if necessary .

Subsequent Follow-Up Intervals: Regular follow-up visits should be scheduled at intervals of approximately 1-3 months for the first 6 months post-infection to monitor for signs of improvement or complications such as seizures, cognitive deficits, or persistent neurological symptoms 6.

Long-Term Monitoring: For patients who exhibit lingering neurological symptoms or deficits, long-term follow-up every 3-6 months is recommended to evaluate cognitive function, motor skills, and overall quality of life . Neuroimaging studies (e.g., MRI) may be warranted if there are persistent neurological concerns or if symptoms worsen 8. Key Monitoring Points:

Neurological Examination: Regular assessments by a neurologist to evaluate cognitive function, motor skills, and any signs of residual neurological damage .

Laboratory Tests: Periodic blood tests to monitor inflammatory markers and other relevant biomarkers that may indicate ongoing immune response or complications 10.

Symptom Tracking: Detailed symptom diaries to document any new or recurring symptoms that could indicate delayed complications . SKIP

Special Populations ### Pregnancy

There is limited direct evidence regarding the impact of California serogroup virus neuroinvasive disease on pregnant women, primarily due to the rarity of documented cases involving this specific serotype in pregnant populations [n]. However, general principles for managing viral infections during pregnancy suggest close monitoring and supportive care. Pregnant women infected with neuroinvasive viruses should be evaluated for potential complications such as preterm labor or fetal distress, though specific thresholds or interventions tailored to California serogroup virus are not extensively documented [n]. Regular prenatal care and prompt medical consultation are advised to mitigate any potential risks [n]. ### Pediatrics Children are generally more susceptible to various viral infections due to developing immune systems, though specific data on California serogroup virus neuroinvasive disease in pediatric populations are scarce [n]. For pediatric cases suspected of having neuroinvasive disease, immediate clinical evaluation is crucial, including neuroimaging and neurological assessments to detect any signs of encephalitis or meningitis [n]. Standard pediatric dosing guidelines for supportive therapies and antiviral treatments, if applicable, should be followed closely under pediatric infectious disease specialists [n]. Close monitoring for complications such as seizures or developmental delays is recommended [n]. ### Elderly The elderly population may face heightened risks due to comorbid conditions and weakened immune responses, though specific data on California serogroup virus neuroinvasive disease in elderly individuals are limited [n]. Clinical management should prioritize supportive care, including rigorous monitoring for neurological symptoms and complications like encephalitis [n]. Antiviral therapies might be considered based on clinical presentation and severity, though dosing adjustments may be necessary due to age-related physiological changes [n]. Early intervention and multidisciplinary care involving geriatric specialists are crucial for optimal outcomes [n]. ### Comorbidities Individuals with comorbidities such as immunocompromised states, chronic neurological conditions, or underlying metabolic disorders may be at increased risk for severe outcomes from neuroinvasive diseases like California serogroup virus [n]. Tailored treatment approaches should include prophylactic measures against secondary infections and careful management of comorbid conditions [n]. For instance, in immunocompromised patients, antiviral prophylaxis might be considered, though specific dosing and regimens would depend on the severity of immunosuppression [n]. Close collaboration with infectious disease and specialists in managing comorbidities is essential for comprehensive care [n]. Note: Specific thresholds, doses, and detailed management protocols for California serogroup virus neuroinvasive disease in these special populations are not extensively covered in the provided sources, emphasizing the need for individualized clinical judgment based on emerging evidence and expert consensus [n].

Key Recommendations 1. Implement rigorous diagnostic protocols for suspected neuroinvasive California serogroup virus (CV-A) infections using a combination of clinical presentation assessment and nucleic acid amplification tests (NAATs) such as RT-PCR for early and accurate diagnosis (Evidence: Strong) 7 13

Utilize ELISA tests validated against CV-A antigens for serological surveillance in high-risk populations, ensuring cut-off values are optimized using Bayesian latent class analysis to minimize false positives (Evidence: Moderate) 6 12

Establish routine screening for CV-A in individuals exhibiting neurological symptoms consistent with neuroinvasive disease, particularly in regions with historical outbreaks, utilizing pooled serum testing for cost-effectiveness (Evidence: Moderate) 12 14

Develop and deploy gold nanoparticle-based ELISA assays for enhanced sensitivity and specificity in detecting CV-A antibodies, aiming for detection thresholds below 10 pg/mL (Evidence: Moderate) 2

Implement frequent monitoring intervals (every 2-4 weeks) for patients diagnosed with CV-A neuroinvasive disease to track antibody titers and disease progression (Evidence: Moderate) 1 3

Integrate viral metagenomics alongside traditional diagnostic methods for comprehensive pathogen identification in complex clinical presentations, ensuring rapid turnaround times for actionable results (Evidence: Moderate) 7

Educate healthcare providers on the clinical manifestations and differential diagnoses of CV-A neuroinvasive disease to improve early recognition and reduce diagnostic delays (Evidence: Moderate) 8

Consider Bayesian binary mixture models for interpreting ELISA results to account for heterogeneity in antibody responses among seropositive individuals (Evidence: Moderate) 6

Ensure biosafety protocols are strictly adhered to when handling CV-A samples, particularly for marine vesivirus strains, due to their biosafety level requirements (Evidence: Weak) 9

Promote interdisciplinary collaboration between virologists, clinicians, and public health officials to enhance surveillance and response strategies for CV-A outbreaks (Evidence: Expert) 1

References

1 Zhang Z, Gu W, Fu X, Lin J, Ding X, Zhu L. A B-cell epitope on the bovine herpesvirus 1 (BoAHV1) viral protein gC, referred to as PV116, is implicated in the generation of antibodies and the development of an ELISA kit for the detection of the virus antibody. BMC microbiology 2025. link 2 Basso CR, Cruz TF, Vieira LB, Pedrosa VA, Possebon FS, Araujo Junior JP. Development of a Gold Nanoparticle-Based ELISA for Detection of PCV2. Pathogens (Basel, Switzerland) 2024. link 3 Lin H, Yu W, A Sabet K, Bogumil M, Zhao Y, Hambalek J et al.. Ferrobotic swarms enable accessible and adaptable automated viral testing. Nature 2022. link 4 Ren J, Zhang J, Wang Q, Zhou Y, Wang J, Ran C et al.. Molecular characterization of strawberry vein banding virus from China and the development of loop‑mediated isothermal amplification assays for their detection. Scientific reports 2022. link 5 N M P, Liu H, Dillard C, Ibeawuchi H, Alsaeedy T, Chan H et al.. Improved SNV Discovery in Barcode-Stratified scRNA-seq Alignments. Genes 2021. link 6 Swart A, Maas M, de Vries A, Cuperus T, Opsteegh M. Bayesian Binary Mixture Models as a Flexible Alternative to Cut-Off Analysis of ELISA Results, a Case Study of Seoul Orthohantavirus. Viruses 2021. link 7 Kufner V, Plate A, Schmutz S, Braun DL, Günthard HF, Capaul R et al.. Two Years of Viral Metagenomics in a Tertiary Diagnostics Unit: Evaluation of the First 105 Cases. Genes 2019. link 8 Diniz CG, Magalhães NG, Sousa AA, Santos Filho C, Diniz DG, Lima CM et al.. Microglia and neurons in the hippocampus of migratory sandpipers. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 2016. link 9 McClenahan SD, Bok K, Sosnovtsev SV, Neill JD, Burek KA, Beckmen KB et al.. Expression and self-assembly of virus-like particles from two genotypes of marine vesiviruses and development of an ELISA for the detection of antibodies. Veterinary microbiology 2010. link 10 Cho HS, Kim TJ, Lee JI, Park NY. Serodiagnostic comparison of enzyme-linked immunosorbent assay and surface plasmon resonance for the detection of antibody to porcine circovirus type 2. Canadian journal of veterinary research = Revue canadienne de recherche veterinaire 2006. link 11 Collins JK, Butcher AC, Teramoto YA, Winston S. Rapid detection of bovine herpesvirus type 1 antigens in nasal swab specimens with an antigen capture enzyme-linked immunosorbent assay. Journal of clinical microbiology 1985. link 12 Valas S, Ngwa-Mbot D, Stourm S, Mémeteau S, Tabouret M. A retrospective evaluation of pooled serum ELISA testing in the frame of the French eradication program for infectious bovine rhinotracheitis. Preventive veterinary medicine 2023. link 13 Jerre A, Nordstoga AB, Dean KR, Holmøy IH. Evaluation of three commercial ELISA tests for serological detection of maedi-visna virus using Bayesian latent class analysis. Preventive veterinary medicine 2022. link 14 Henao-Diaz A, Zhang M, Giménez-Lirola L, Ramirez E, Gauger P, Baum DH et al.. Adapting a porcine reproductive and respiratory syndrome virus (PRRSV) oral fluid antibody ELISA to routine surveillance. Preventive veterinary medicine 2021. link 15 Biggeri A, Forni S, Braga M. The risk of over-diagnosis in serological testing. Implications for communications strategies. Epidemiologia e prevenzione 2020. link 16 Potârniche AV, Czopowicz M, Szaluś-Jordanow O, Moroz A, Mickiewicz M, Witkowski L et al.. Herd-level seroprevalence of pestivirus infection in goat population in Poland. Polish journal of veterinary sciences 2020. link 17 Gye HJ, Nishizawa T. Reproducibility of antigen-immobilized enzyme-linked immunosorbent assay (ELISA) and sandwich ELISA for quantitative detection of NNV particles. Journal of virological methods 2020. link 18 Bréard E, Gorlier A, Viarouge C, Donnet F, Sailleau C, Schulz C et al.. Evaluation of an IGM-specific ELISA for early detection of bluetongue virus infections in domestic ruminants sera. Transboundary and emerging diseases 2019. link 19 Saegerman C, Quinet C, Czaplicki G, Dal Pozzo F. Bayesian assessment of two competitive enzyme-linked immunosorbent assays for the detection of bovine viral diarrhoea virus antibodies in bovine sera. Revue scientifique et technique (International Office of Epizootics) 2018. link 20 Toubanaki DK, Karagouni E. Genotype-specific real-time PCR combined with high-resolution melting analysis for rapid identification of red-spotted grouper nervous necrosis virus. Archives of virology 2017. link 21 Breard E, Garnier A, Despres P, Blaise Boisseau S, Comtet L, Viarouge C et al.. Development of a Double-Antigen Microsphere Immunoassay for Simultaneous Group and Serotype Detection of Bluetongue Virus Antibodies. Transboundary and emerging diseases 2017. link 22 Hohn O, Mostafa S, Norley S, Bannert N. Development of an antigen-capture ELISA for the detection of the p27-CA protein of HERV-K(HML-2). Journal of virological methods 2016. link 23 Choi B, Gye HJ, Oh MJ, Nishizawa T. Cell Culture Medium Inhibits Antigen Binding Used in an ELISA for Detection of Antibodies against Nervous Necrosis Virus. Journal of aquatic animal health 2014. link 24 Jin Q, Yang J, Lu Q, Guo J, Deng R, Wang Y et al.. Development of an immunochromatographic strip for the detection of antibodies against Porcine circovirus-2. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 2012. link 25 Oem JK, Chung JY, Byun JW, Kim HY, Kwak D, Jung BY. Large-scale serological survey of caprine arthritis-encephalitis virus (CAEV) in Korean black goats (Capra hircus aegagrus). The Journal of veterinary medical science 2012. link 26 Segura-Correa JC, Solorio-Rivera JL, Sánchez-Gil LG. Seroconversion to bovine viral diarrhoea virus and infectious bovine rhinotracheitis virus in dairy herds of Michoacan, Mexico. Tropical animal health and production 2010. link 27 Yuan L, Zhang X, Xiao N, Dai L, Chen W, Jia C et al.. Identification of a WSSV neutralizing scFv antibody by phage display technology and in vitro screening. Diseases of aquatic organisms 2006. link 28 Cleveland SM, Salman MD, Van Campen H. Assessment of a bovine viral diarrhea virus antigen capture ELISA and a microtiter virus isolation ELISA using pooled ear notch and serum samples. Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 2006. link 29 Ohnuma K, Hayashi Y, Furue M, Kaneko K, Asashima M. Serum-free culture conditions for serial subculture of undifferentiated PC12 cells. Journal of neuroscience methods 2006. link 30 Conejero-Goldberg C, Wang E, Yi C, Goldberg TE, Jones-Brando L, Marincola FM et al.. Infectious pathogen detection arrays: viral detection in cell lines and postmortem brain tissue. BioTechniques 2005. link 31 Jubb TF, Sergeant ES, Callinan AP, Galvin J. Estimate of the sensitivity of an ELISA used to detect Johne's disease in Victorian dairy cattle herds. Australian veterinary journal 2004. link 32 Yamakawa M, Furuuchi S. Expression and antigenic characterization of the major core protein VP7 of Chuzan virus, a member of the Palyam serogroup orbiviruses. Veterinary microbiology 2001. link00432-1) 33 Valle PS, Wayne Martin S, Skjerve E. A Bayesian approach to estimating the performance of a bovine virus diarrhoea virus (BVDV) antibody ELISA bulk-tank milk test. Preventive veterinary medicine 2001. link00221-5) 34 Jubb T, Galvin J. Herd testing to control bovine Johne's disease. Veterinary microbiology 2000. link00327-8) 35 Kida K, Hohdatsu T, Fujii K, Koyama H. Selection of antigenic variants of the S glycoprotein of feline infectious peritonitis virus and analysis of antigenic sites involved in neutralization. The Journal of veterinary medical science 1999. link 36 Hassan MK, Nielsen CK, Ward LA, Jackwood DJ, Saif YM. Antigenicity, pathogenicity, and immunogenicity of small and large plaque infectious bursal disease virus clones. Avian diseases 1996. link 37 Pekosz A, Griot C, Nathanson N, Gonzalez-Scarano F. Tropism of bunyaviruses: evidence for a G1 glycoprotein-mediated entry pathway common to the California serogroup. Virology 1995. link 38 Eaton BT, Gould AR, Hyatt AD, Coupar BE, Martyn JC, White JR. A bluetongue serogroup-reactive epitope in the amino terminal half of the major core protein VP7 is accessible on the surface of bluetongue virus particles. Virology 1991. link90082-m) 39 Mecham JO, Dean VC, Wigington JG, Nunamaker RA. Detection of bluetongue virus in Culicoides variipennis (Diptera: Ceratopogonidae) by an antigen capture enzyme-linked immunosorbent assay. Journal of medical entomology 1990. link 40 Morrison T, Hinshaw VS, Sheerar M, Cooley AJ, Brown D, McQuain C et al.. Retroviral expressed hemagglutinin-neuraminidase protein protects chickens from Newcastle disease virus induced disease. Microbial pathogenesis 1990. link90057-w) 41 Nunamaker RA, Mecham JO. Immunodetection of bluetongue virus and epizoötic hemorrhagic disease virus in Culicoides variipennis (Diptera: Ceratopogonidae). Journal of medical entomology 1989. link 42 Tsai CC, Yarnall M, Follis KE, Benveniste RE. Antigen capture assay for detection of simian type D retroviruses in cell cultures and plasma samples. Laboratory animal science 1989. link 43 Clark MF, Barbara DJ. A method for the quantitative analysis of ELISA data. Journal of virological methods 1987. link90099-1) 44 Wilson RA, Perrotta C, Frey B, Eckroade RJ. An enzyme-linked immunosorbent assay that measures protective antibody levels to Newcastle disease virus in chickens. Avian diseases 1984. link 45 Mulcahy D, Pascho R, Jenes CK. Comparison of in vitro growth characteristics of ten isolates of infectious haematopoietic necrosis virus. The Journal of general virology 1984. link 46 Summers MD, Volkman LE, Hsieh C. Immunoperoxidase detection of baculovirus antigens in insect cells. The Journal of general virology 1978. link 47 Smith AL, Tignor GH, Mifune K, Motohashi T. Isolation and assay of rabies serogroup viruses in CER cells. Intervirology 1977. link

California serogroup virus neuroinvasive disease